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Introduction
Homocysteine (Hcy) is a sulfur-containing amino acid metabolized 
either by the remethylation pathway to methionine or the trans-
sulfuration pathway to cysteine; each pathway depends on other 
series of biochemical enzymes such as methionine synthetase 
and methylene tetrahydrofolate reductase as well as vitamin 
B12 and folic acid. A later pathway is dependent on the enzymes 
cystathionine β-synthetase and pyridoxine (vitamin B6). Any loss 
of one of those pathways and/or a dietary deficiency can result 
in an elevated Hcy level.1) Therefore, Hcy level may be influenced 
by factors such as nutrition, genetics, lifestyle, ethnicity, age, 
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and gender.1)2) Epidemiological studies have demonstrated that 
progression of atherosclerosis plaques is correlated with elevated 
circulating Hcy due to increased thrombogenicity, oxidative stress 
status and endothelial dysfunction.3)4) Consequently, a recent large 
prospective study reported an independent association of elevated 
Hcy level with coronary artery disease (CAD), and the prognostic 
value of elevated Hcy level is well validated in Caucasians, both in 
the general population and in the patients with CAD.5-9) However, 
there are limited data regarding the prognostic value of elevated 
Hcy in other ethnicities. Because Hcy level may be influenced by 
ethnicity, it is not certain whether elevated Hcy level is associated 
with worse outcome in Korean patients with CAD. Therefore, we 
sought to evaluate the prognostic value of elevated Hcy level in 
such Korean patients.
Subjects and Methods
Study design and patient selection
A total of 5839 patients (60.4% male, mean age 61.3±11.2  years) 
with CAD from 2000 to 2010 at Gangnam Severance Hospital were 
enrolled. CAD was diagnosed by invasive coronary angiography. 
Laboratory values including Hcy level were obtained on the day 
of coronary angiography and analyses were performed shortly 
after sampling. Patients were divided into two groups according 
to their Hcy levels. Baseline risk factors, coronary angiographic 
findings, length of follow-up, and composite endpoints including 
cardiac death (CD) and non-fatal myocardial infarction (NFMI) were 
recorded. Institutional review committee approval and informed 
consent were obtained.
Definition of variables
Risk factors were recorded as categorical variables in all patients. 
Hypertension was defined as systolic blood pressure≥140 mmHg and/or 
diastolic blood pressure≥90 mmHg, or by antihypertensive prescription. 
Type 2 diabetes was defined by hypoglycemic agents or insulin prescription, 
fasting plasma glucose≥126 mg/dL, glycosylated hemoglobin≥6.5%, 
or known but untreated hyperglycemia. Hyperlipidemia was defined 
by total cholesterol≥240 mg/dL, triglycerides≥200 mg/dL, low-
density lipoprotein cholesterol≥130 mg/dL, high-density lipoprotein 
cholesterol<40 mg/dL, and/or by lipid-lowering prescription. A patient 
was considered a smoker, if the patient currently smoked or had smoked 
up until 1 month prior to the baseline coronary angiography. Non-
obstructive CAD was defined as <50% luminal narrowing, whereas 
obstructive CAD was defined as ≥50% luminal narrowing. The extent 
of obstructive CAD was categorized according to the number of vessels 
involved (1, 2, or 3).
Laboratory measurements
Total cholesterol, triglycerides, low-density lipoprotein cholesterol, 
and high-density lipoprotein cholesterol were measured directly 
using colorimetric and turbidimetric assays with an autoanalyzer 
AU5800 (Beckman Coulter, Irvine, CA, USA). Hcy measurement was 
determined using a commercially available enzymatic colorimetric 
assay AU5800 (Beckman Coulter, Irvine, CA, USA), and the values 
were expressed in μmol/L. Patients were divided into two groups 
according to the respective Hcy concentration levels: 1) normal Hcy 
group (lower two tertiles [Hcy median value 7.9 μmol/L, range: 0.1-
10.3 μmol/L]) and 2) elevated Hcy group (upper tertile [Hcy median 
value 12.5 μmol/L, range: 10.4-94.0 μmol/L]).
Endpoint determination and follow-up data acquisition
Composite endpoints were defined as CD or NFMI. To avoid 
treatment bias, coronary artery revascularization procedures, 
such as coronary artery bypass graft surgery and percutaneous 
coronary intervention, were not regarded as endpoints.10) For 
patients with multiple cardiovascular events, only the first event 
was considered for analysis. Cardiac death was defined as death 
caused by acute myocardial infarction, ventricular arrhythmias, 
refractory heart failure, or cardiogenic shock. Diagnosis of NFMI 
required the presence of at least two of the three following 
criteria: characteristic chest pain, elevated cardiac enzymes, or 
electrocardiographic alterations indicative of myocardial infarction. 
Patient follow-up data were collected using electronic medical 
record reviews and/or standardized telephone interviews.
Statistical analysis
Continuous data were expressed as a mean value±standard 
deviation. All categorical data were presented as a percentage or 
an absolute number. Analyses of continuous data were performed 
using independent t-test and analyses of categorical data were 
performed using chi-square test to assess differences between 
the two groups. The C-statistic for the logistic regression model 
used for calculation of the propensity score matching for the 2 
groups was 0.66. Patients with elevated Hcy level were then 1-to-1 
matched to the patients with normal Hcy level on the propensity 
scores using the nearest available pair matching method. The 
procedure yielded 1818 well-matched pairs. Cumulative event 
rates as a function over time were estimated using the Kaplan-
Meier method, and survival curves of composite CD/NFMI were 
compared using the log-rank test for both the entire cohort and 
the propensity score matched cohort. Univariate and multivariate 
Cox regression analyses were performed to determine associations 
between clinical characteristics (age, gender, hypertension, 
smoking, and hyperlipidemia), lipid parameters, Hcy, extent of CAD 
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and clinical outcome in both the entire cohort and the propensity 
score-matched cohort. Hazard ratios (HRs) were calculated as 
an estimate of the risk associated with a particular variable with 
95% confidence intervals (CIs), based on binomial distributions. All 
analyses were performed using SPSS version 19.0 (SPSS, Chicago, IL, 
USA). A p of less than 0.05 was considered statistically significant.
Results
Of the 5839 patients in the study, 60.4% were male and the 
mean age was 61.3±11.2 years. Mean Hcy level was 9.9±4.3 μmol/L 
(7.9±1.5 μmol/L for normal Hcy groups and 13.9±5.1 μmol/L for 
elevated Hcy group, respectively). A summary of the baseline 
characteristics of both the entire cohort and propensity matched 
cohort according to the Hcy level is shown in Table 1. Patients 
with elevated Hcy levels tended to be older (p<0.0001), male 
(p<0.0001), diabetic (p=0.003), hypertensive (p<0.0001), smoker 
(p<0.0001), and hyperlipidemic (p<0.0001) (Table 1). More patients 
with elevated Hcy level had acute coronary syndrome at their 
clinical presentation (p<0.0001) (Table 1). A summary of laboratory 
and angiographic characteristics of both the entire cohort and the 
propensity matched cohort according to the Hcy level is shown 
in Table 2. Patients with elevated Hcy level had higher triglyceride 
levels (p=0.020) and lower high-density lipoprotein cholesterol 
levels (p<0.0001) (Table 2). In addition, elevated Hcy level showed an 
association with higher rates of both obstructive CAD (p<0.0001) 
and 3-vessel obstructive CAD (p<0.0001), at the time of baseline 
coronary angiography (Table 2). Consequently, higher coronary 
revascularization rates as well as coronary bypass graft surgery 
rates were observed in patients with elevated Hcy level (Table 2).
Clinical outcomes
Over a mean follow-up period of 4.4±2.5 years, there were 132 
composite endpoints (75 CD and 57 NFMI) with an event rate of 
2.3%. The composite CD/NFMI rates were 1.5% (60/3886) and 
3.7% (72/1953) for the normal Hcy and the elevated Hcy group, 
respectively, which were significantly different (p<0.0001) (Fig. 
1A). In multivariate Cox proportional survival analysis, age (HR 
1.054, 95% CI 1.035-1.073, p<0.0001), diabetes (HR 2.137, 95% CI 
1.052-3.039, p<0.0001), obstructive CAD (HR 3.226, 95% CI 1.721-
6.047, p<0.0001), and elevated Hcy (HR 2.077, 95% CI 1.467-2.941, 
p<0.0001) were independent risk factors for composite CD/NFMI 
(Table 3A). 
Propensity score matched analysis
After performing propensity score matching, a total of 1818 
matched pairs (1818 patients from the normal Hcy group and 1818 
patients from the elevated Hcy group) were generated. There were 
no significant differences in baseline, laboratory and angiographic 
characteristics for the propensity score matched subjects except 
for Hcy levels (Tables 1 and 2). A total of 97 composite endpoints 
(56 CD and 41 NFMI) occurred during the follow-up period in 
the matched cohorts. The respective composite CD/NFMI rates 
were 1.9% (34/1818) and 3.5% (63/1818) for normal Hcy and 
elevated Hcy group. The elevated Hcy group was associated with 
Table 1. Baseline clinical characteristics according to Hcy levels
Total cohort (n=5839) Propensity score matched cohort (n=3636)
Normal Hcy Elevated Hcy p Normal Hcy Elevated Hcy p
Age (years) 59.9±10.8 63.9±11.5 <0.0001 62.7±10.2 63.3±11.4 0.111
Male gender 2109/3886 (54.3) 1416/1953 (72.5) <0.0001 1318/1818 (72.5) 1298/1818 (71.4) 0.460
Diabetes 854/3886 (22.0) 497/1953 (25.4) 0.003 465/1818 (25.6) 458/1818 (25.2) 0.790
Hypertension 1998/3886 (51.4) 1140/1953 (58.4) <0.0001 1045/1818 (57.5) 1052/1818 (57.9) 0.814
Smoking 1046/3886 (26.9) 669/1953 (34.3) <0.0001 636/1818 (35.0) 614/1818 (33.8) 0.442
Hyperlipidemia 2508/3886 (64.5) 1372/1953 (70.3) <0.0001 1260/1818 (69.3) 1273/1818 (70.0) 0.639
Clinical diagnosis <0.0001 0.653
Silent IHD 611/3886 (15.7) 398/1953 (20.4) 349/1818 (19.2) 354/1818 (19.5)
Stable angina 1740/3886 (44.8) 836/1953 (42.8) 825/1818 (45.4) 782/1818 (43.0)
Unstable angina 1090/3886 (28.0) 510/1953 (26.1) 453/1818 (24.9) 485/1818 (26.7)
NSTEMI 216/3886 (5.6) 114/1953 (5.8) 101/1818 (5.6) 107/1818 (5.9)
STEMI 229/3886 (5.9) 95/1953 (4.9) 90/1818 (5.0) 90/1818 (5.0)
Data are expressed as number (%) or mean±standard deviation. Hcy: homocysteine, IHD: ischemic heart disease, NSTEMI: non-ST elevation myocardial in-
farction, STEMI: ST elevation myocardial infarction
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Table 2. Laboratory and angiographic characteristics according to Hcy levels
Total cohort (n=5839) Propensity score matched cohort (n=3636)
Normal Hcy Elevated Hcy p Normal Hcy Elevated Hcy        p
Total cholesterol (mg/dL) 171.6±37.4 169.9±40.0 0.139 170.4±37.8 170.5±40.0 0.934
Triglycerides (mg/dL) 135.6±84.2 141.0±83.4 0.020 138.6±79.3 140.9±83.0 0.397
LDL-C (mg/dL) 105.9±32.3 106.0±34.1 0.938 106.2±32.3 106.1±34.2 0.948
HDL-C (mg/dL) 44.7±11.4 42.3±11.4 <0.0001 43.0±10.5 42.6±11.5 0.334
Hcy (μmol/L) 7.9±1.5 13.9±5.1 <0.0001 8.1±1.4 13.8±4.8 <0.0001
Obstructive CAD 2404/3886 (61.9) 1366/1953 (69.9) <0.0001 1263/1818 (69.5) 1258/1818 (69.2) 0.857
Extent of CAD <0.0001 0.339
Non-obstructive CAD 1482/3886 (38.1) 587/1953 (30.1) 555/1818 (30.5) 560/1818 (30.8)
1VD 1005/3886 (25.9) 449/1953 (23.0) 443/1818 (24.4) 422/1818 (23.2)
2VD 699/3886 (18.0) 375/1953 (19.2) 378/1818 (20.8) 352/1818 (19.4)
3VD 700/3886 (18.0) 542/1953 (27.8) 442/1818 (24.3) 484/1818 (26.6)
Revascularization 1764/3886 (45.4) 996/1953 (51.0) <0.0001 946/1818 (52.0) 924/1818 (50.8) 0.465
BMS 509/3886 (13.1) 256/1953 (13.1) 259/1818 (14.2) 240/1818 (13.2)
DES 1041/3886 (26.8) 554/1953 (28.4) 547/1818 (30.1) 512/1818 (28.2)
CABG 214/3886 (5.5) 186/3886 (9.5) 140/1818 (7.7) 172/1818 (9.5)
Data are expressed as number (%) or mean±standard deviation. Hcy: homocysteine, LDL-C: low density lipoprotein cholesterol, HDL-C: high density lipo-
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Fig. 1. Kaplan-Meier survival analysis according to Hcy levels. (A) Total cohort and (B) propensity score matched cohort. Hcy: homocysteine. CD: cardiac 
death, NFMI: non-fatal myocardial infarction.
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significantly worse outcomes than the normal Hcy group in the 
matched cohort (p=0.001) (Fig. 1B). In addition, in the multivariate 
analysis, the elevated Hcy group still had almost 2-fold higher risk 
for composite CD/NFMI, when compared to the normal Hcy group 
(HR 1.982, 95% CI 1.305-3.009, p=0.001) (Table 3B).
Discussion
Hcy is an intermediate metabolite of methionine that contributes 
to atherosclerosis through several mechanisms, such as endothelial 
dysfunction, increased permeability of lipid and inflammatory 
Table 3. Univariate and multivariate Cox regression analysis for predicting composite CD/NFMI in (a) total cohort and (b) propensity score matched cohort
(A) Total cohort
Univariate Multivariate
HR 95% CI p HR 95% CI p
Age 1.068 1.049-1.087 <0.0001 1.054 1.035-1.073 <0.0001
Male gender 1.238 0.861-1.779 0.249
Diabetes 2.623 1.858-3.703 <0.0001 2.137 1.502-3.039 <0.0001
Hypertension 1.480 1.036-2.116 0.031 1.006 0.697-1.452 0.973
Smoking 1.090 0.759-1.563 0.641
Hyperlipidemia 1.280 0.869-1.884 0.212
Obstructive CAD 3.853 2.212-6.713 <0.0001 3.226 1.721-6.047 <0.0001
Extent of CAD <0.0001
Non-obstructive CAD   1.000  (reference)
1VD 2.160 1.122-4.159 0.021
2VD 2.438 1.243-4.781 0.010
3VD 7.017 3.951-12.460 <0.0001
Hcy 2.571 1.824-3.622 <0.0001 2.077 1.467-2.941 <0.0001
Revascularization 1.534 1.075-2.188 0.018 0.766 0.514-1.141 0.190
(B) Propensity score matched cohort
Univariate Multivariate
HR 95% CI p HR 95% CI p
Age 1.059 1.037-1.082 <0.0001 1.053 1.030-1.076 <0.0001
Male gender 0.773 0.504-1.185 0.237
Diabetes 2.695 1.808-4.019 <0.0001 2.360 1.580-3.527 <0.0001
Hypertension 1.273 0.841-1.927 0.253
Smoking 0.943 0.623-1.429 0.783
Hyperlipidemia 1.232 0.776-1.955 0.376
Obstructive CAD 3.301 1.714-6.358 <0.0001 2.499 1.289-4.844 0.007
Extent of CAD <0.0001
Non-obstructive CAD 1.000 (reference)
1VD 2.029 0.936-4.398 0.073
2VD 1.995 0.896-4.442 0.091
3VD 5.461 2.777-10.738 <0.0001
Hcy 2.001 1.318-3.038 0.001 1.982 1.305-3.009 0.001
Revascularization 1.328 0.878-2.008 0.179
CD: cardiac death, NFMI: non-fatal myocardial infarction, HR: hazard ratio, CI: confidence interval, CAD: coronary artery disease, VD: vessel disease, Hcy: homocysteine 
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cells, lipoprotein oxidation, vascular inflammation, smooth muscle 
proliferation, platelet activation, and abnormalities in the clotting 
cascade.11-13) During the process of Hcy metabolism pathways, any 
interference of one of those pathways and/or a dietary deficiency 
can result in elevation of Hcy level.1) Therefore, Hcy level may be 
influenced by factors such as nutrition, genetics, lifestyle, ethnicity, 
age, and gender.1) Previous study by Cappuccio et al.2) reported the 
discordance of Hcy levels which differ among Caucasians, African 
origins, and South Asians living in England, suggested a variance 
of the Hcy level between ethnicities. Another study reported that 
the frequency of the homozygous dominant mutation genotype of 
the enzyme methylene tetrahydrofolate reductase (C677T gene) is 
higher in the Hispanic population in the United States compared 
to other populations.14) Since, genetic polymorphism of methylene 
tetrahydrofolate reductase affects the Hcy level, the ethnic 
differences of this enzyme polymorphism may result in variations 
in Hcy level.
A recent large prospective cohort study reported an association 
of elevated Hcy level with the severity as well as the presence of 
CAD.5) This study confirmed this association even after correction 
for baseline differences, suggesting an independent role of Hcy 
in prediction of CAD risk. In addition, since the Hcy level may be 
influenced by ethnicity, several previous cross-sectional studies 
from non-Caucasian populations reported the association between 
Hcy level and CAD. Baños-González et al.15) reported an association 
of elevated Hcy with CAD in a Hispanic male population. Another 
study by Ghassibe-Sabbagh et al.16) reported an association 
of elevated Hcy with CAD in a Middle East Asian population. 
Kumakura et al.17) reported an association of elevated Hcy with CAD 
in Japanese patients with peripheral artery disease. Consistent with 
these studies, our study demonstrated that elevated Hcy levels 
have positive correlation with both the presence and extent of CAD 
in the Korean population.
Previous meta-analysis study by Homocysteine Studies 
Collaboration consisting of 30 prospective or retrospective studies 
reported that elevated Hcy is a modest independent predictor of 
ischemic heart disease in a healthy population.6) In addition, a recent 
study suggested that elevated Hcy level has additive prognostic 
value in terms of predicting adverse cardiac events in the general 
population.7) With regard to the prognostic value of elevated Hcy 
level in other ethnic general populations, Sun et al.18) reported a 
significant association of elevated Hcy level with cardiovascular 
events and all cause mortality in the general Chinese population.
The prognostic value of elevated Hcy in patients with CAD is still 
a subject under debate. Previous study reported that elevated Hcy 
level was not associated with worse prognosis in patients with 
CAD.19) In contrast, other study reported that elevated Hcy level 
was a strong predictor of mortality in patients with CAD.8) Another 
study reported an association of elevated Hcy level with adverse 
cardiac events in patients with CAD.9) However, aforementioned 
studies on the prognostic value of elevated Hcy level in patients 
with CAD were conducted in Caucasians. In the context of these 
conflicting findings, we evaluated the prognostic value of elevated 
Hcy level in non-Caucasian (Korean) patients with CAD. In our 
study, we demonstrated the distribution of Hcy level in Korean 
patients with CAD. Besides, we documented that elevated Hcy 
level is associated with worse outcome in Korean patients with 
CAD, even after propensity score matching for other confounding 
variables. Therefore, we believe that our data support the clinical 
value of determining elevated Hcy level in Korean patients with 
CAD.
There are several limitations in our study. First, this was an 
observational study conducted at a single center. Second, there are 
no data for vitamin cofactors (vitamin B6 and B12 and folic acid) 
required for Hcy metabolism, all of which may affect the Hcy levels. 
Pharmacological interferences such as vitamin B/folate intake 
administration or some genetic mutations might have played a role 
in modifying Hcy levels.20) However, several randomized controlled 
trials and a recent meta-analysis have shown that Hcy-lowering 
interventions with vitamin B/folate supplementation did not reduce 
the occurrence of cardiovascular events, particularly coronary 
heart disease.21-26) In conclusion, an elevated Hcy level is associated 
with worse outcomes in Korean patients with CAD.
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